DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Delamanid
Delamanid
Analysis of Mutations Leading to Para-Aminosalicylic Acid Resistance in Mycobacterium Tuberculosis
Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
Updated WHO MDR-TB Treatment Guidelines and the Use of New Drugs in Children
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Six-Month Response to Delamanid Treatment in MDR TB Patients
Estonian Statistics on Medicines 2016 1/41
Treatment of Drug-Resistant Tuberculosis an Official ATS/CDC/ERS/IDSA Clinical Practice Guideline Payam Nahid, Sundari R
MDR-TB): Evidence and Perspectives
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
List Item European Medicines Agency Recommends Two
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: the Role of Bedaquiline and Delamanid
Rapid in Vivo Detection of Isoniazid-Sensitive Mycobacterium Tuberculosis by Breath Test
WO 2018/048944 Al 15 March 2018 (15.03.2018) W !P O PCT
Page 1 FINLANDS FÖRFATTNINGSSAMLING Utgiven I Helsingfors
New Ways to Treat Tuberculosis Using Dendrimers As Nanocarriers
A5343 a Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Pa
Zāļu Patēriņa Statistika 2018
Laakeluettelo-Liite 1
Top View
Version 9.0 October 2017
DR-TB DRUGS UNDER the MICROSCOPE SOURCES and PRICES for DRUG-RESISTANT TUBERCULOSIS MEDICINES 3Rd Edition – October 2013
Mechanisms of Drug Resistance in Mycobacterium Tuberculosis: Update 2015
WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment
Deltyba® (Delamanid)
Final Treatment Outcomes of Delamanid-Containing Regimens in Patients with MDR-/XDR-TB in South Korea
Critically Important Antimicrobials for Human Medicine – 5Th Revision. Geneva
CYCLOSERINE, PRETOMANID and SIRTURO®
Delamanid for Rifampicin–Resistant Tuberculosis: a Retrospective Study from South Africa
The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis Interim Policy Guidance
Data Sheet of Clinical Trial C.T
Large-Scale Chemical-Genetics Yields New Mycobacterium Tuberculosis Inhibitor Classes
Bedaquiline and Delamanid for the Treatment of Multidrug-Resistant Tuberculosis: a Multicentre Cohort Study in Korea
Bedaquiline- and Delamanid- Containing Regimens Achieve Excellent Interim Treatment Response Without Safety Concerns Endtb Inter
CONSERVING the USE of CRITICALLY IMPORTANT ANTIMICROBIALS in FOOD-PRODUCING ANIMALS Gaps and Possibilities in Global Guidance and Indian Policy Framework
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Resistant Tuberculosis in South Africa: Policy Framework
Dr-Tb Drugs Under the Microscope Issue Issue Brief 6Th Edition
Early Experience with Delamanid-Containing Regimens in the Treatment of Complicated Multidrug-Resistant Tuberculosis in Hong Kong
Reptb: a Gene Ontology Based Drug Repurposing Approach for Tuberculosis Anurag Passi1,2, Neeraj Kumar Rajput1, David J
WHO Best-Practice Statement on the Off-Label Use of Bedaquiline and Delamanid for the Treatment of Multidrug-Resistant Tuberculosis
American Thoracic Society Documents
242-08-210 Amendment 1
Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: a Systematic Review
Deltyba, INN-Delamanid
Who-Pq Recommended Summary of Product Characteristics
Drug Resistance Mechanisms in Mycobacterium Tuberculosis
An Activist's Guide to Tuberculosis Drugs 2016 Update
Critically Important Antimicrobials for Human Medicine, 6Th Revision
The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents Interim Policy Guidance
Potency Boost of a Mycobacterium Tuberculosis Dihydrofolate Reductase Inhibitor by Multienzyme F420H2-Dependent Reduction
Multi-Omics Technologies Applied to Tuberculosis Drug Discovery
Adverse Events Among People on Delamanid for Rifampicin- Resistant Tuberculosis in a High HIV Prevalence Setting
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Entscheidung Der Arzneimittelbehörde
Notes from the Field: Acquisition of Delamanid Under A
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
Tuberculosis Drug Discovery and Development 2019 Development and Discovery Drug Tuberculosis • Giovanna Riccardi and Claudia Sala and Riccardi • Giovanna
In Vitro Interaction Profiles of the New Antitubercular Drugs Bedaquiline
New Inhibitors of Mycobacterium Tuberculosis Identified Using Systems Chemical Biology
Evaluation of Clinical Drug Interaction Potential of Clofazimine Using Static and Dynamic Modeling Approaches S
Drug-Resistant Tuberculosis: a Survival Guide for Clinicians
Delamanid Improves Outcomes and Reduces Mortality in Multidrug-Resistant Tuberculosis
Key Changes to the Treatment of Multidrug- and Rifampicin-Resistant TB
New Drugs for the Treatment of Tuberculosis
Deltyba, INN-Delamanid
First Case of Extensively Drug-Resistant Tuberculosis Treated with Both Delamanid and Bedaquiline